H.C. Wainwright lowered the firm’s price target on Atai Life Sciences to $15 from $20 and keeps a Buy rating on the shares following the Q4 report. The analyst remains “very positive” on Atai’s pipeline, and the potential value realization for shareholders in the next year as multiple data readouts further validate pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Rising High: Exclusive talk with financial services firm Safe Harbor Financial
- Atai Life Sciences sees cash runway into 2026
- Atai Life Sciences reports Q4 EPS (12c), consensus (16c)
- atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
- Atai Life announces initial results from Psytech’s Phase 2a study of BPL-003
